国林科技最新一期业绩显示，截至2025一季报，公司营业总收入1.15亿元、同比增长18.79%，归属净利 润611.14万元，同比减少42.53%，扣非净利润629.12万元，同比减少41.88%，流动比率1.985、速动比率 0.991、资产负债率34.20%。 天眼查商业履历信息显示，青岛国林科技集团股份有限公司，成立于1994年，位于青岛市，是一家以从 事专用设备制造业为主的企业。企业注册资本18401.5879万人民币，实缴资本3585万人民币。公司法定 代表人为丁香鹏。 通过天眼查大数据分析，青岛国林科技集团股份有限公司共对外投资了8家企业，参与招投标项目422 次，知识产权方面有商标信息14条，专利信息72条，此外企业还拥有行政许可53个。 来源：金融界 金融界消息 截至2025年7月29日收盘，国林科技（300786）报收于15.33元，下跌0.45%，换手率 5.94%，成交量8.71万手，成交金额1.33亿元。 资金流向方面，今日主力资金净流出1865.82万元，占比成交额13.99%。其中，超大单净流出503.11万 元、占成交额3.77%，大单净流出1362.72万元、占成交额10.21 ...

证券代码：300786 证券简称：国林科技 公告编号：2025-053 青岛国林科技集团股份有限公司 上述专利技术不会对公司目前生产经营直接产生重大影响，但有利于公司进 一步完善知识产权保护体系，形成持续创新机制，提升公司的技术实力和核心竞 争力。 特此公告。 青岛国林科技集团股份有限公司 董事会 关于取得专利证书的公告 2025年7月14日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 青岛国林科技集团股份有限公司（以下简称"公司"）于近日收到国家知识 产权局颁发的实用新型专利证书，具体情况如下： | 用于纸浆漂白的 | 第23074163 | ZL2024 2 | 2024年9月23日 | 实用新型 | | --- | --- | --- | --- | --- | | 专利名称 装置 | 证书号 号 | 专利号 2316100.7 | 专利申请日期 | 专利类型 专利 | 本实用新型专利"用于纸浆漂白的装置"公开了一种用于纸浆漂白的臭氧工 艺装置，包括供氧组件、臭氧发生器、臭氧气水混合罐、气液混合泵、臭氧纸浆 漂白器和臭氧尾气破坏器，气液混合泵的进气 ...

Core Viewpoint - The A-share market shows a mixed performance with 476 stocks breaking through the five-day moving average, indicating potential investment opportunities in certain sectors [1] Group 1: Market Overview - As of 10:29 AM, the Shanghai Composite Index is at 3432.93 points, below the five-day moving average, with a fluctuation of 0.25% [1] - The total trading volume of A-shares today is 693.146 billion yuan [1] Group 2: Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Morningstar Aviation (晨曦航空) with a deviation of 15.14% and a price increase of 19.99% [2] - Qifeng Precision (七丰精工) with a deviation of 11.69% and a price increase of 15.15% [2] - Awatech (阿为特) with a deviation of 10.02% and a price increase of 14.90% [2] - Other notable stocks with significant price increases and deviations include: - Xiongtai Technology (雄帝科技) with an 11.52% increase and an 8.85% deviation [2] - Songsheng Co. (崧盛股份) with a 10.85% increase and an 8.36% deviation [2] Group 3: Additional Stocks with Positive Performance - Other stocks showing positive performance and deviations include: - Lijun Co. (利君股份) with a 9.97% increase and a 7.69% deviation [2] - Xiangyu Medical (翔宇医疗) with a 10.41% increase and a 7.66% deviation [2] - Chengfei Integration (成飞集成) with a 10.00% increase and a 7.58% deviation [2]

Core Viewpoint - The company reported a significant increase in revenue for 2024, but continued to face substantial net losses, indicating ongoing financial challenges despite revenue growth [1][2]. Financial Performance Summary - For the year 2024, the company achieved operating revenue of 493.04 million yuan, representing a year-on-year increase of 23.33% compared to 399.77 million yuan in 2023 [2]. - The net profit attributable to shareholders was -49.96 million yuan, a decline of 71.46% from -29.14 million yuan in the previous year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -54.84 million yuan, an 86.87% decrease from -29.34 million yuan in 2023 [2]. - The net cash flow from operating activities was -30.23 million yuan, worsening by 78.99% from -16.89 million yuan in the previous year [2]. Q1 2025 Performance Summary - In the first quarter of 2025, the company reported operating revenue of 11.49 million yuan, an 18.79% increase year-on-year [3]. - The net profit attributable to shareholders for Q1 2025 was -6.11 million yuan, a 42.53% increase in losses compared to -4.29 million yuan in the same period last year [3]. - The net cash flow from operating activities improved to 10.75 million yuan, a 130.77% increase from -34.95 million yuan in Q1 2024 [3]. Capital Raising Activities - The company was listed on the Shenzhen Stock Exchange on July 23, 2019, raising a total of 343.74 million yuan from the public offering of 13.35 million shares at a price of 26.02 yuan per share, after deducting issuance costs [3]. - In a subsequent capital raising event, the company raised 359.99 million yuan, with net proceeds of 350.74 million yuan after deducting issuance expenses [4]. - The total amount raised by the company from both fundraising activities is approximately 707 million yuan [4].

Group 1 - The A-share photoresist concept has experienced significant upward movement, with Xingye Co., Ltd. hitting the daily limit [1] - Other companies such as Aisikai, Jiuri New Materials, Ruilian New Materials, Baotong Technology, Huamao Technology, and Guolin Technology also saw increases in their stock prices [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Xinjiang Guolin New Materials Co., Ltd., will suspend production for maintenance on the "25,000 tons/year high-quality crystal acetaldehyde project" starting from June 3, 2025, for approximately 60 days [1] Group 1 - The maintenance plan is expected to last around 60 days, with the specific resumption date dependent on the actual maintenance duration [1] - The company will fulfill its information disclosure obligations regarding the progress of this maintenance in accordance with relevant regulations [1] - Investors are advised to pay attention to investment risks associated with this production suspension [1]

关于子公司停产检修的公告 证券代码：300786 证券简称：国林科技 公告编号：2025-052 青岛国林科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 2025年6月3日 特此公告。 青岛国林科技集团股份有限公司 董事会 根据化工企业生产工艺特点，为保障生产装置正常运行和安全稳定生产，青 岛国林科技集团股份有限公司（以下简称"公司"）的全资子公司新疆国林新材 料有限公司（以下简称"新疆国林"）拟按照检修计划对"2.5万吨/年高品质晶 体乙醛酸项目"生产线进行停产检修工作。 新疆国林拟于2025年6月3日起对"2.5万吨/年高品质晶体乙醛酸项目"生产 线进行停产检修，预计检修计划时间60天左右，具体复产时间以实际检修时间为 准。针对此次停产检修，公司已做好相关产品的供应预案，确保现有订单的安全 稳定供应，不会对公司经营情况造成较大影响。 公司将根据相关规定就本次停产检修进展情况及时履行信息披露义务，敬请 广大投资者注意投资风险。 ...

本实用新型专利"喷射装置"有助于提高臭氧在覆膜表面布气的均匀性，有 利于增强覆膜的粘性，促进覆膜的粘附效果，同时提高臭氧的利用率，保证产品 的良率。该项专利技术暂未应用到公司现有产品中。 证券代码：300786 证券简称：国林科技 公告编号：2025-053 关于取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 青岛国林科技集团股份有限公司（以下简称"公司"）于近日收到国家知识 产权局颁发的实用新型专利证书，具体情况如下： | 专利名称 | 证书号 | 专利号 | 专利申请日期 | 专利类型 | | --- | --- | --- | --- | --- | | 臭氧发生器 | 第22911934号 | ZL 2024 2 1479662.7 | 2024年6月26日 | 实用新型 | | 喷射装置 | 第22906718号 | ZL 2024 2 1979555.0 | 2024年8月15日 | 实用新型 | 本实用新型专利"臭氧发生器"通过将接地电极板件、垫片和介质板件之间 围合形成螺旋形介质阻挡放电气隙，能够增加氧气电离的时间，有利于 ...

Core Viewpoint - The demand for glycolic acid in China is steadily increasing, projected to rise from 98,000 tons in 2022 to 108,000 tons in 2024, driven by its applications in pharmaceuticals, fragrances, and food additives, as well as emerging sectors like lithium battery electrolytes and biodegradable plastics [1][12]. Industry Overview - Glycolic acid is an organic compound with the formula C2H2O3, characterized by its white crystalline form and various industrial applications [2]. - The market for glycolic acid is expanding due to rising living standards and increased demand in various sectors [1][12]. Production Methods - The primary production methods for glycolic acid include oxalic acid electrolysis, glyoxal nitric oxidation, and ozone oxidation of anhydride, with domestic producers predominantly using glyoxal nitric oxidation [3][4]. Industry Chain - The glycolic acid industry chain involves upstream sectors like petrochemicals and biomass energy, providing essential raw materials, while downstream applications span pharmaceuticals, pesticides, dyes, and food additives [8]. Market Competition - The Chinese glycolic acid market is characterized by a dominance of large enterprises, with significant players including Hubei Hongyuan Pharmaceutical and Qingdao Guolin Technology, while smaller firms focus on niche markets [16][17]. Industry Development Trends - Innovations in production processes, such as using biomass-derived acetyl acid, are expected to enhance efficiency and product quality [21]. - Increased international cooperation is anticipated, particularly under the Belt and Road Initiative, which may expand market share and enhance technological capabilities [22]. - The pharmaceutical sector's growth is likely to broaden the consumption of glycolic acid, solidifying its market position as a crucial raw material for various drugs [24].

北京德和衡律师事务所 关于青岛国林科技集团股份有限公司 2024年年度股东大会的 法律意见书 德和衡证见意见(2025)第00095号 北京德和衡律师事务所 www.deheng.com.cn 中国北京市朝阳区建国门外大街 2 号银泰中心 C 座 11、12 层 Tel：010-85407666 邮编：100022 北京德和衡律师事务所 关于青岛国林科技集团股份有限公司 2024年年度股东大会的 法律意见书 德和衡证见意见(2025)第00095号 致：青岛国林科技集团股份有限公司 北京德和衡律师事务所（以下简称"本所"）接受青岛国林科技集团股份有限公司（以下 简称"公司"）的委托，指派本所律师出席贵公司 2024 年年度股东大会。本所律师依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《青岛国林科技集团股份有限公司章程》（以下简称"《公司章程》"）及 相关法律法规，就本次股东大会的有关事宜出具本法律意见书。 本法律意见书仅就本次股东大会的召集和召开程序、会议召集人和出席会议人员的资格、 会议表决程序和表决结果的合法有效性等发表意见，并不对本次 ...